The Pharmaceutical Contract Manufacturing Market size is estimated to grow from USD 188.16 Billion in 2022 to reach USD 318.96 Billion by 2030, growing at a CAGR of 6.82% during the forecast period from 2023 to 2030.
Major players in Pharmaceutical Contract Manufacturing Market include: Abbvie, Inc., Thermo Fisher Scientific, Inc., Lonza Group, Catalent, Inc., Evonik Industries Ag, Samsung Biologics, Fujifilm Holdings Corporation, Siegfried Holding Ag, Eurofins Scientific, Wuxi Apptec, Boehringer Ingelheim International Gmbh, Recipharm AB, Vetter Pharma, Piramal Pharma Solutions, and Almac Group
Globally rising healthcare expenses are one of the key reasons for rising demand for generic pharmaceuticals. Many countries' healthcare systems are under pressure to keep costs under control while providing high-quality medical treatment to an aging population. Generic medications provide a cost-effective answer because they are often 30% to 80% less expensive than brand-name equivalents. Patients and healthcare providers are increasingly turning to generic alternatives to cut healthcare costs while maintaining therapeutic efficacy.
Additionally, government initiatives and regulations supporting the use of generic pharmaceuticals have played an important role in increasing demand. Many governments have developed generic substitution policies, which encourage or require the use of generic medications when they are available. Such initiatives are frequently motivated by the desire to reduce healthcare costs and improve patient access to important pharmaceuticals. In some circumstances, healthcare providers may be compensated for recommending generic pharmaceuticals, further encouraging their use.
In addition, the rising prevalence of chronic diseases and age-related ailments has increased the demand for long-term pharmaceuticals. Chronic illnesses frequently necessitate ongoing pharmacological therapy, resulting in substantial prescription expenses for patients. Because generic medications are more affordable, patients are more likely to stick to their prescribed prescriptions, resulting in improved illness control. However, despite the rising demand for generic medications, specific challenges persist. Some patients and healthcare providers may hesitate to convert from brand-name to generic pharmaceuticals due to worries about efficacy or potential formulation variations. Pharmaceutical companies must address these concerns by undertaking rigorous bioequivalence studies that establish the similarity of generic medications to brand-name equivalents.
Moreover, as the generic pharmaceutical industry evolves, pharmaceutical companies and healthcare stakeholders will need to work together to assure the availability and quality of generic drugs to satisfy the demands of patients and healthcare systems.
The recent development of biologics has completely changed the pharmaceutical sector and led to substantial investments in R&D. Biologics are complex, requiring state-of-the-art manufacturing techniques and specialized equipment. As a result, the market for pharmaceutical contract manufacturing has experienced rapid expansion as pharmaceutical companies look for knowledge in large-scale biologic production. A major part of ensuring the effective and economical production of biologics is played by contract manufacturers with advanced bioprocessing capabilities, enabling more patient access to these potentially life-saving treatments.
Furthermore, the growing prevalence of complicated diseases has prompted collaborations among pharmaceutical companies, research institutes, and contract manufacturers to hasten the discovery and marketing of novel therapeutics. These agreements promote knowledge sharing, expertise exchange, and resource pooling, all of which contribute to breakthroughs in biological and advanced therapeutic manufacturing processes.
Moreover, the biopharmaceutical market in North America is expanding fast, mainly to advances in biotechnology and the rising frequency of chronic diseases. Contract manufacturers play an important role in assisting biopharmaceutical businesses in efficiently bringing their novel drugs to market.
The Pharmaceutical Contract Manufacturing Market research report provides an in-depth overview of the industry including market segmentation by Services, End-user, and Region. Analysis of the global market with a special focus on high-growth applications in each vertical and fast-growing market segment. It includes a detailed competitive landscape with identification of the key players concerning each type of market, in-depth market share analysis with individual revenue, market shares, and top players’ rankings. Impact analysis of the market dynamics with factors currently driving and restraining the growth of the market, along with their impact in the short, medium, and long-term landscapes. Competitive intelligence from the company profiles, key player strategies, and game-changing developments such as new product launches, collaborations, expansions, investment analysis, mergers, and acquisitions. The market analysis focuses on revenue and forecast by region/countries and by application in terms of revenue forecast for the period 2023-2030.
The report further studies the market strategies of key players, recent development status, plans, and Pharmaceutical Contract Manufacturing Market trends across the world. Also, it splits the market segmentation further to deep dive into research and reveals company profile and prospects.
This product will be delivered within 3-5 business days.
Major players in Pharmaceutical Contract Manufacturing Market include: Abbvie, Inc., Thermo Fisher Scientific, Inc., Lonza Group, Catalent, Inc., Evonik Industries Ag, Samsung Biologics, Fujifilm Holdings Corporation, Siegfried Holding Ag, Eurofins Scientific, Wuxi Apptec, Boehringer Ingelheim International Gmbh, Recipharm AB, Vetter Pharma, Piramal Pharma Solutions, and Almac Group
Increase in Demand for Generic Drugs
Generic pharmaceuticals are identical or bioequivalent versions of brand-name prescriptions, but they are marketed at a reduced cost since they do not require the same amount of research and development effort. This affordability has made generic pharmaceuticals more accessible to individuals, healthcare providers, and healthcare systems.Globally rising healthcare expenses are one of the key reasons for rising demand for generic pharmaceuticals. Many countries' healthcare systems are under pressure to keep costs under control while providing high-quality medical treatment to an aging population. Generic medications provide a cost-effective answer because they are often 30% to 80% less expensive than brand-name equivalents. Patients and healthcare providers are increasingly turning to generic alternatives to cut healthcare costs while maintaining therapeutic efficacy.
Additionally, government initiatives and regulations supporting the use of generic pharmaceuticals have played an important role in increasing demand. Many governments have developed generic substitution policies, which encourage or require the use of generic medications when they are available. Such initiatives are frequently motivated by the desire to reduce healthcare costs and improve patient access to important pharmaceuticals. In some circumstances, healthcare providers may be compensated for recommending generic pharmaceuticals, further encouraging their use.
In addition, the rising prevalence of chronic diseases and age-related ailments has increased the demand for long-term pharmaceuticals. Chronic illnesses frequently necessitate ongoing pharmacological therapy, resulting in substantial prescription expenses for patients. Because generic medications are more affordable, patients are more likely to stick to their prescribed prescriptions, resulting in improved illness control. However, despite the rising demand for generic medications, specific challenges persist. Some patients and healthcare providers may hesitate to convert from brand-name to generic pharmaceuticals due to worries about efficacy or potential formulation variations. Pharmaceutical companies must address these concerns by undertaking rigorous bioequivalence studies that establish the similarity of generic medications to brand-name equivalents.
Moreover, as the generic pharmaceutical industry evolves, pharmaceutical companies and healthcare stakeholders will need to work together to assure the availability and quality of generic drugs to satisfy the demands of patients and healthcare systems.
Growing prevalence of complex diseases and the emergence of biologics and advanced therapies
The emergence of biologics and cutting-edge medicines as well as the rising prevalence of complex disorders are two interrelated variables that have had a major impact on the healthcare environment. Traditional therapy modalities frequently fall short in offering efficient remedies as the burden of complicated diseases, such as cancer, autoimmune disorders, and chronic problems, continues to climb internationally. A new age in medical science has begun as a result of the investigation and creation of novel biologics and cutting-edge treatments.The recent development of biologics has completely changed the pharmaceutical sector and led to substantial investments in R&D. Biologics are complex, requiring state-of-the-art manufacturing techniques and specialized equipment. As a result, the market for pharmaceutical contract manufacturing has experienced rapid expansion as pharmaceutical companies look for knowledge in large-scale biologic production. A major part of ensuring the effective and economical production of biologics is played by contract manufacturers with advanced bioprocessing capabilities, enabling more patient access to these potentially life-saving treatments.
Furthermore, the growing prevalence of complicated diseases has prompted collaborations among pharmaceutical companies, research institutes, and contract manufacturers to hasten the discovery and marketing of novel therapeutics. These agreements promote knowledge sharing, expertise exchange, and resource pooling, all of which contribute to breakthroughs in biological and advanced therapeutic manufacturing processes.
Regional Insight
North America, which comprises the United States and Canada, is a major center for pharmaceutical production and research, making it a popular location for contract manufacturing services. North American pharmaceutical corporations are progressively outsourcing their manufacturing operations to contract manufacturers. Outsourcing allows pharmaceutical businesses to concentrate on their core competencies, such as research and development, while contract manufacturers manage the production and supply chain components of medication manufacturing. In addition, the increased emphasis on specialist therapeutics such as biologics, personalized medications, and gene therapies necessitates the development of specialized manufacturing capabilities. Contract manufacturers frequently have the skills and infrastructure to handle the complicated production procedures associated with these sophisticated treatments, making them an appealing alternative for pharmaceutical companies.Moreover, the biopharmaceutical market in North America is expanding fast, mainly to advances in biotechnology and the rising frequency of chronic diseases. Contract manufacturers play an important role in assisting biopharmaceutical businesses in efficiently bringing their novel drugs to market.
The Pharmaceutical Contract Manufacturing Market research report provides an in-depth overview of the industry including market segmentation by Services, End-user, and Region. Analysis of the global market with a special focus on high-growth applications in each vertical and fast-growing market segment. It includes a detailed competitive landscape with identification of the key players concerning each type of market, in-depth market share analysis with individual revenue, market shares, and top players’ rankings. Impact analysis of the market dynamics with factors currently driving and restraining the growth of the market, along with their impact in the short, medium, and long-term landscapes. Competitive intelligence from the company profiles, key player strategies, and game-changing developments such as new product launches, collaborations, expansions, investment analysis, mergers, and acquisitions. The market analysis focuses on revenue and forecast by region/countries and by application in terms of revenue forecast for the period 2023-2030.
The report further studies the market strategies of key players, recent development status, plans, and Pharmaceutical Contract Manufacturing Market trends across the world. Also, it splits the market segmentation further to deep dive into research and reveals company profile and prospects.
Major Classifications are as follows:
By Services
- Active Pharmaceutical Ingredient (API) Manufacturing Services
- Biopharmaceutical Contract Manufacturing / Biomanufacturing Services
- Bioprocess and Biologics Development Services
- Bioprocess Engineering Services
- Custom Peptide Synthesis Services
- Large-Scale Protein Production Services
- Contract Clinical Trial Materials (CTM) Manufacturing Services
- Liquid and Semi-Solid Dosage Form Contract Manufacturing Services
- Potent Compound and Cytotoxic Therapy Manufacturing Services
- Solid Dosage Forms Contract Manufacturing Services
By End-user
- Big Pharmaceutical Companies
- Biotechnology Companies
- Biopharma Companies
- Generic Pharmaceutical Companies
- Academic Institutes,
- Others
By Region
- North America
- US
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Rest of Asia Pacific
- Rest of the World
- Middle East
- UAE
- Saudi Arabia
- Israel
- Rest of the Middle East
- Africa
- South Africa
- Rest of the Middle East & Africa
Reason to Purchase this Pharmaceutical Contract Manufacturing Market Report:
- Determine prospective investment areas based on a detailed trend analysis of the global Pharmaceutical Contract Manufacturing Market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different Pharmaceutical Contract Manufacturing Market segments in the top spending countries across the world and identify the opportunities each offers.
- Strengthen your understanding of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels that are driving the global Pharmaceutical Contract Manufacturing Market, providing a clear picture of future opportunities that can be tapped, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs that are being undertaken by the different countries within the global Pharmaceutical Contract Manufacturing Market.
- Make correct business decisions based on a thorough analysis of the total competitive landscape of the sector with detailed profiles of the top Pharmaceutical Contract Manufacturing Market providers worldwide, including information about their products, alliances, recent contract wins, and financial analysis wherever available.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Key Takeaways
Research Methodology
Market Overview
Market Dynamics
Pharmaceutical Contract Manufacturing Market, By Services
Pharmaceutical Contract Manufacturing Market, By End-User
Pharmaceutical Contract Manufacturing Market, By Geography
Competitive Analysis
Company Profiles
Companies Mentioned
- Abbvie, Inc.
- Thermo Fisher Scientific, Inc.
- Lonza Group
- Catalent, Inc.
- Evonik Industries Ag
- Samsung Biologics
- Fujifilm Holdings Corporation
- Siegfried Holding Ag
- Eurofins Scientific
- Wuxi Apptec
- Boehringer Ingelheim International Gmbh
- Recipharm AB
- Vetter Pharma
- Piramal Pharma Solutions
- Almac Group
